Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo.
Gallium, when bound to transferrin, has been previously shown to cause tumor cell cytotoxicity by preventing cellular uptake of transferrin bound iron in vitro. Patients treated with constant infusion gallium nitrate for carcinoma show a rise in serum iron within 6 hr of the start of treatment. Serum iron returns to baseline by 24 hr post-infusion. Atomic analysis of iron and gallium content of Sephadex G-150 fractions of treatment sera indicate that about an equimolar amount of gallium and iron are associated with transferrin. These gallium and iron concentrations result in inhibition of transferrin mediated iron uptake in vitro, and in vivo allow for > 90% saturation of transferrin with metal. All seven patients who completed two courses of gallium therapy exhibited hypochromic microcytic anemia (mean fall in hemoglobin 3.5 grams %). Evidence for red cell iron depletion was confirmed by an increase (mean 3.3-fold) in zinc protoporphyrin levels. Since transferrin receptor increases on gallium treated iron requiring cells in vitro, we assessed cell surface transferrin receptor on peripheral blood lymphocytes by measuring fluorescent transferrin receptor antibody binding. A population of highly transferrin receptor positive cells peaks at 48 hr into the infusion. DNA analysis as well as double staining indicate the majority of transferrin receptor positive cells are unstimulated B lymphocytes. These studies provide the first documentation that constant infusion gallium treatment results in significant interference with iron metabolism and evidence for tissue iron depletion in vivo. These changes may correlate with therapeutic effects of gallium such as tumor response.
Seligman
P A
PA
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Moran
P L
PL
Schleicher
R B
RB
Crawford
E D
ED
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001773:Blood Cells / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000378:metabolism; D004334:Drug Administration Schedule; D005708:Gallium / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000097:blood / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011990:Receptors, Transferrin / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D011990:Receptors, Transferrin; D005708:Gallium; D007501:Iron; C027235:gallium nitrate